Bio-Techne TECH 深 沪
已收盘 08-21 16:00:00 美东时间
72.32
+0.040
+0.06%
华盛通- 最 高72.35
- 今 开72.32
- 成交量 395.80万股
- 最 低 72.27
- 昨 收 72.28
- 总市值 112.68亿
- 52周最高 72.62
- 市盈率 静 62.34
- 换手率 2.54%
- 52周最低 43.115
- 委 比 -62.62%
- 总股本 1.56亿
- 历史最高 134.4425
- 量 比 1.46
- 振 幅 0.11%
- 历史最低 11.6125
- 每 手 1
- 风险率 7.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73
Wells Fargo analyst Brandon Couillard downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $62 to $73.
08-14 05:36
Bio-Techne Corrects Dividend Announcement
MINNEAPOLIS, Aug. 13, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stat...
08-13 18:30
Bio-Techne declares $0.08 dividend
Bio-Techne (TECH) declares $0.08/share quarterly dividend, in line with previous. Forward yield 0.44% Payable Aug. 28; for shareholders of record Aug. 17; ex-div Aug. 17. See TECH Dividend Scorecard, ...
08-12 18:54
财报速睇 | Bio-Techne 2026财年Q2营收3.21亿美元，同比增长1.3%；归母净利润0.55亿美元，扭亏为盈
华盛资讯8月12日讯，Bio-Techne公布2026财年Q2业绩，公司Q2营收3.21亿美元，同比增长1.3%，归母净利润0.55亿美元，扭亏为盈。
08-12 18:47
Bio-Techne Q4 Adj. EPS $0.52, Inline, Sales $321.191M Beat $314.679M Estimate
Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is a 1.89 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $321.191 million which beat the analyst consensus...
08-12 18:41
Bio-Techne Declares Dividend
MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended ...
08-12 18:30
Bio-Techne 2026财年第四季度业绩：有机营收增长3% 调整后每股收益下滑
Bio-Techne 2026财年第四季度营收同比增长1%至3.212亿美元，有机增长率为3%。GAAP稀释后每股收益由上年同期的每股亏损0.11美元改善至0.35美元，主要反映了本期无需计提上年同期的持有待售资产减值；调整后每股收益则从0.53美元微降至0.52美元。诊断与空间生物学业务实现8%的有机增长，板块利润率提升至11.2%；但受销量和产品组合不利因素影响，蛋白质科学业务的利润率降至42.0%。目前，德国默克（Merck KGaA）拟以每股73美元现金进行的收购案仍是该公司最核心的焦点事件。
08-12 10:44
Biotech stocks lead healthcare's overbought list as earnings picks up
Healthcare stocks are in focus as second-quarter earnings season shifts into high gear, with investors evaluating whether recent rallies across biotech, medical technology and healthcare services can ...
07-23 19:18
